Live
Endpoints NewsDid Eli Lilly just strike another gold mine?Endpoints NewsWhat’s familiar in health tech’s Q1 funding totalsEndpoints NewsStudy suggests $35 monthly insulin cap has increased patient accessPromega BlogNew Study Suggests Cancer Research Has an Age ProblemEndpoints NewsWhite House adds AbbVie's Humira to TrumpRx alongside cheaper biosimilarsBioPharma DiveTerns rebuffed a higher bid before selling to MerckFierceBiotechLilly pays AC Immune $12.5M to expand Alzheimer’s collab as asset draws closer to clinicFierceBiotechLongtime Hologic CEO Steve MacMillan to retire as $18.3B deal closesFierceBiotechOwlet CEO exits suddenly, co-founder returns to the nestFierceBiotechE2 lands $80M series C for next gen thrombectomy treatmentFierceBiotechCRO Fortrea launches AI-powered solution to improve trial efficiencyBioWorldAppointments and advancements for April 7, 2026
Endpoints News Feb 18, 2026

Novartis signs macrocyclic deal with Unnatural Products for $100M upfront

Novartis signs macrocyclic deal with Unnatural Products for $100M upfront

Original
Body unavailable. Use the original source.

Directory

59 All